Literature DB >> 18571764

Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type.

Hironori Ninomiya1, Miyako Hiramatsu, Kentaro Inamura, Kimie Nomura, Michiyo Okui, Tatsu Miyoshi, Sakae Okumura, Yukitoshi Satoh, Ken Nakagawa, Makoto Nishio, Takeshi Horai, Satoshi Miyata, Eiju Tsuchiya, Masashi Fukayama, Yuichi Ishikawa.   

Abstract

The presence of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) mutations significantly correlates with tumor sensitivity to TK inhibitors, particularly in lung adenocarcinomas, the predominant histological subtype in Japan and the United States. To clarify links between EGFR mutations and pathological findings in Japanese lung cancer, detailed pathological features of adenocarcinomas were examined using the WHO criteria as well as our cell type classification (hobnail, columnar and polygonal). Medical records were reviewed for a total of 107 surgically resected tumors. Clinicopathological factors were examined and correlations with EGFR status were evaluated. EGFR mutations were found in 63 patients (59%) distributed through all four exons examined (through exons 18-21). EGFR mutations were significantly associated with female gender (P=0.003), non-smoker status (P=0.008) and hobnail cell morphology (P<0.00001). In addition, detailed pathological examination showed significant associations with bronchioloalveolar carcinoma (BAC) component and a micropapillary pattern (MPP) (P=0.012 and 0.043, respectively). We conclude that characteristic histological features, i.e. the hobnail cell morphology and the presence of BAC component and MPP are good predictors of EGFR mutations in lung adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18571764     DOI: 10.1016/j.lungcan.2008.04.017

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  30 in total

1.  Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update.

Authors:  Gillian Bethune; Drew Bethune; Neale Ridgway; Zhaolin Xu
Journal:  J Thorac Dis       Date:  2010-03       Impact factor: 2.895

Review 2.  Implementing the new IASLC/ATS/ERS classification of lung adenocarcinomas: results from international and Chinese cohorts.

Authors:  Ming-Ching Lee; Kyuichi Kadota; Daniel Buitrago; David R Jones; Prasad S Adusumilli
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

3.  Expression level of CRKL and AXL combined with exon 19 deletion in EGFR and ALK status confer differential prognosis of lung adenocarcinoma subtypes.

Authors:  Yi-Ran Cai; Yu-Jie Dong; Hong-Bo Wu; Da-Ping Yu; Li-Juan Zhou; Dan Su; Li Zhang; Xue-Jing Chen
Journal:  Oncol Lett       Date:  2016-09-02       Impact factor: 2.967

4.  Targeted Therapies in Lung Cancer.

Authors:  Lucian R Chirieac; Sanja Dacic
Journal:  Surg Pathol Clin       Date:  2010-03-01

5.  Genetic alterations in lung adenocarcinoma with a micropapillary component.

Authors:  Masashi Furukawa; Shinichi Toyooka; Kouichi Ichimura; Hiromasa Yamamoto; Junichi Soh; Shinsuke Hashida; Mamoru Ouchida; Kazuhiko Shien; Hiroaki Asano; Kazunori Tsukuda; Shinichiro Miyoshi
Journal:  Mol Clin Oncol       Date:  2015-12-02

6.  Molecular alterations in a new cell line (KU-Lu-MPPt3) established from a human lung adenocarcinoma with a micropapillary pattern.

Authors:  Yukiko Matsuo; Kazu Shiomi; Dai Sonoda; Masashi Mikubo; Masahito Naito; Yoshio Matsui; Tsutomu Yoshida; Yukitoshi Satoh
Journal:  J Cancer Res Clin Oncol       Date:  2017-11-01       Impact factor: 4.553

Review 7.  International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

8.  Clinicopathological Significance of Micropapillary Pattern in Lung Adenocarcinoma.

Authors:  Jung-Soo Pyo; Joo Heon Kim
Journal:  Pathol Oncol Res       Date:  2017-07-06       Impact factor: 3.201

9.  Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas.

Authors:  Daisuke Matsubara; Shumpei Ishikawa; Oguni Sachiko; Hiroyuki Aburatani; Masashi Fukayama; Toshiro Niki
Journal:  Am J Pathol       Date:  2010-10-07       Impact factor: 4.307

10.  Recent advances and clinical implications of the micropapillary histological subtype in lung adenocarcinomas.

Authors:  Ming-Ching Lee; Daniel H Buitrago; Kyuichi Kadota; David R Jones; Prasad S Adusumilli
Journal:  Lung Cancer Manag       Date:  2014-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.